Esteban Londoño

Esteban Londoño

Auto-generated profile, based on publicly available information

Esteban Londoño

Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization , Washington, DC

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Global Health Action
Verified
Journal Article
Open access
EAEsteban Londoño Agudelo
Esteban Londoño Agudelo
AFAnaí García Fariñas
Anaí García Fariñas
VOViviana Pérez Ospina
Viviana Pérez Ospina
CPCecilia Taborda Pérez
Cecilia Taborda Pérez
TLTatiana Villacrés Landeta
Tatiana Villacrés Landeta
PSPatrick Van der Stuyft
Patrick Van der Stuyft
Hypertension requires life-long medical care, which may cause economic burden and even lead to catastrophic health expenditure. To estimate the extent of out-of-pocket expenditure for hypertension ...

12 May 2025 in Revista Panamericana de Salud Pública
Verified
Journal Article
Open access
PDF file
VIVilma Irazola
Vilma Irazola
CPCarolina Prado
Carolina Prado
ARAndres Rosende
Andres Rosende
DFDavid Flood
David Flood
RTRoss Tsuyuki
Ross Tsuyuki
POPedro Ordunez
Pedro Ordunez
Cardiovascular diseases remain the leading cause of premature morbidity and mortality globally, with hypertension as their main modifiable risk factor. In Latin America and the Caribbean, hypertension affects more than 30% of adults, yet control rates remain alarmingly low. The HEARTS in the Americas Initiative, led by the Pan American Health Organization, promotes a model of team-based care to enhance risk management for hypertension and cardiovascular diseases within primary health care. Team-based care leverages the skills of diverse health professionals, including nurses, pharmacists and community health workers, to optimize resource allocation, task-sharing and care delivery. Evidence underscores the effectiveness of team-based care in improving blood pressure control, reducing hospitalizations and enhancing quality of life through strategies such as periodic follow up and medication titration. Despite its benefits, implementing team-based care faces cultural and systemic barriers. This special report outlines a policy framework to scale team-based care across the Region of the Americas, ensuring equitable access to high-quality, cost-effective prevention and care for cardiovascular diseases.

1 December 2025 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
ELEsteban Londoño
Esteban Londoño
RGReena Gupta
Reena Gupta
PSPatrick Van der Stuyft
Patrick Van der Stuyft
Martin HeineMartin Heine
Martin Heine
GGGloria Giraldo
Gloria Giraldo
POPedro Ordunez
Pedro Ordunez
HEARTS in the Americas is the largest-scale implementation of the WHO's global initiative, with 33 countries participating, 28 having adopted standardized clinical pathways, and about 10,000 primary healthcare facilities engaged. Despite progress, fragmented care, limited availability of validated blood pressure devices, restricted access to essential medicines, and weak quality assurance systems continue to hinder hypertension control and cardiovascular risk management. In response, PAHO and participating countries co-developed the HEARTS Quality Framework. Grounded in regional implementation, this model synthesizes global evidence and lessons from Latin America and the Caribbean. Co-designed by Ministries of Health, care providers, and international experts, it translates HEARTS strategies into actionable system-level objectives. Clearly defined outcome indicators and implementation targets promote institutionalization, quality improvement, and primary healthcare strengthening—supporting HEARTS scale-up and equitable outcomes. With appropriate contextualization, the HEARTS Quality Framework provides a practical roadmap for countries beyond the Region to advance primary healthcare-based chronic disease care.

3 May 2021 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
EAEsteban Londoño Agudelo
Esteban Londoño Agudelo
VOViviana Pérez Ospina
Viviana Pérez Ospina
TBTullia Battaglioli
Tullia Battaglioli
CPCecilia Taborda Pérez
Cecilia Taborda Pérez
RGRubén Gómez‐Arias
Rubén Gómez‐Arias
PSPatrick Van der Stuyft
Patrick Van der Stuyft
Objectives: To assess hypertension prevalence and the extent and associated factors of hypertension diagnosis, follow‐up, treatment and control gaps in low‐income urban Medellin, Colombia.Methods: We randomly sampled 1873 adults aged 35 or older. Unaware hypertensive individuals were defined as those without previous diagnosis whose average blood pressure was equal to or above 140/90 mmHg. For aware hypertensive patients, control was delimited as average blood pressure below 140/90 if under 59 years old or diabetic, and as less than 150/90 otherwise. We used logistic regression to identify care gap‐associated factors.Results: Hypertension prevalence was 43.5% (95% CI 41.2–45.7). We found 28.2% aware and 15.3% unaware hypertensive individuals, which corresponds to a 35.1% (95% CI 31.9–38.5) underdiagnosis. This gap was determined by age, sex, education and lifestyle factors. 14.4% (95% CI 11.6–17.6) of aware hypertensive patients presented a follow‐up gap, 93.4% (95% CI 90.9–95.2) were prescribed antihypertensive drugs, but 38.9% (95% CI 34.7–43.3) were not compliant. The latter was strongly associated with follow‐up. The hypertension control gap in aware hypertensive patients, 39.0% (95% CI: 34.9–43.2), was associated with being older, having diabetes, weakly adhering to pharmacological treatment and receiving poor non‐pharmacological advice. Overall, 60.4% (95% CI 57.0–63.8) of aware and unaware hypertensive participants had either diagnosed but uncontrolled or undiagnosed hypertension.Conclusions: We found high hypertension prevalence coupled with, from an international perspective, encouraging awareness and control figures. Still, there remains ample room for improvement. Our findings can assist in designing integrated primary healthcare measures that further strengthen equitable and effective access to hypertension care and control.

12 August 2025 in American Journal of Hypertension
Verified
Journal Article
Open access
POPedro Ordunez
Pedro Ordunez
SASonia Y Angell
Sonia Y Angell
DDDonald J DiPette
Donald J DiPette
JBJeffrey Brettler
Jeffrey Brettler
NCNorm Campbell
Norm Campbell
PWPaul K Whelton
Paul K Whelton
BACKGROUND: Inconsistent terminology and conceptual overlap among clinical practice guidelines, treatment protocols, and care pathways can lead to confusion in program design and implementation. METHODS: Drawing on the implementation experience of HEARTS in the Americas—the largest regional adaptation of the WHO Global HEARTS Initiative—this communication describes the characteristics, functions, and interrelationships of clinical practice guidelines, treatment protocols, and care pathways. It outlines their respective roles in development, approval, and execution to clarify their contributions to both health system organization and clinical practice. RESULTS: Clinical practice guidelines are composed of evidence-based recommendations grounded in rigorous scientific evaluation to support clinical decision-making. Care pathways serve as implementation tools that translate guidelines into standardized, multidisciplinary plans that organize hypertension management, facilitate task-sharing, and engage patients. Embedded within pathways, treatment protocols offer a simplified, step-by-step approach tailored to most patients, specifying a limited set of medications and dosages to ensure timely blood pressure control, reduce therapeutic inertia, and promote consistent care delivery. CONCLUSIONS: Clarifying the distinctions and synergies among guidelines, protocols, and care pathways might enhance alignment between clinical guidance and service delivery, supporting effective implementation and scale-up of hypertension and chronic disease management programs.

30 January 2019 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
EAEsteban Londoño Agudelo
Esteban Londoño Agudelo
ASArmando Rodríguez Salvá
Armando Rodríguez Salvá
APAddys Díaz Piñera
Addys Díaz Piñera
RRRené García Roche
René García Roche
PVPol De Vos
Pol De Vos
PSPatrick Van Der Stuyft
Patrick Van Der Stuyft
To determine the prevalence of hypertension treatment and control among hypertensive patients in the Cuban municipalities of Cardenas and Santiago and to explore the main associated predictors. Cross-sectional study, with multistage cluster sampling, conducted between February 2012 and January 2013 in two Cuban municipalities. We interviewed and measured blood pressure in 1333 hypertensive patients aged 18 years or older. Hypertension control was defined as blood pressure lower than 140/90 mmHg. The mean age ± standard deviation (SD) of participants was 59.8 ± 14 years, the mean systolic and diastolic blood pressure ± SD was 130.0 ± 14.4 and 83.1 ± 9.0 mmHg respectively. The majority of patients (91, 95%CI 90–93) were on pharmacological treatment, 49% with a combination of 2 or more classes of drugs. Among diagnosed hypertensive patients 58% (95%CI 55–61) had controlled hypertension. There was no association between hypertension control and gender, age and socio-economic condition. Levels of hypertension control depended on health area and control furthermore was positively associated with post-primary education, not being obese and white ethnicity: adjusted Odds Ratio (95% CI) 1.71 (1.26–2.34), 1.43 (1.09–1.88) and 1.41 (1.09–1.81) respectively. The observed figures are outstanding at the international level and illustrate that hypertension treatment and control are achievable in a resource-constrained setting such as Cuba. The country’s primary health care approach and social equity in access to health care can be seen as key determinants of this success. Nevertheless, there is still room for improvement, as over a third of patients did not have controlled hypertension.